We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters Corp. (WAT) Q2 Earnings and Revenues Trump Estimates
Read MoreHide Full Article
Milford, Massachusetts-based Waters Corporation (WAT - Free Report) is a prominent medical instrument supplying firm, conducting trade in the healthcare sector. The company is renowned analytical instrument producer but also builds and supplies software-based products to its customers.
WAT’s global pharmaceuticals business, its largest single market and major revenue driver, has been gaining traction over the last few quarters and fuelling the growth of Waters Division. The company has a strong presence in the chromatography instrument and pharmaceuticals markets and expects to reap handsome profits from these markets. Additionally, research-intensive product launches coupled with its strong REIMS technology are showing strong future prospects.
However, WAT’s debt level remains a burden, given its recent acquisitions. Also, financial markets in certain foreign countries, especially in Eastern Europe, have been experiencing economic inconsistencies. Such challenging macro conditions, coupled with currency fluctuations, have restricted sales growth rate in recent times. WAT expects these concerns to persist and dampen some of its sales growth momentum to some extent.
Nevertheless, in the last four trailing quarters, WAT has reported a positive average earnings surprise of 2.3%, beating estimates all through.
Currently, WAT has a Zacks Rank #2 (Buy) but that could change following its second-quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: WAT beats on earnings. Adjusted earnings per share came in at $1.58, significantly higher than the Zacks Consensus Estimate of $1.45.
Revenue: Revenues of $537 million came above the Zacks Consensus Estimate of $522 million.
Key Stats: Waters witnessed robust sales growth in Asia (particularly China) and Europe. Also, strong market traction in the bio/pharmaceutical end markets drove the impressive results.
Stock Price: WAT shares were inactive following the release. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on this WAT earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Waters Corp. (WAT) Q2 Earnings and Revenues Trump Estimates
Milford, Massachusetts-based Waters Corporation (WAT - Free Report) is a prominent medical instrument supplying firm, conducting trade in the healthcare sector. The company is renowned analytical instrument producer but also builds and supplies software-based products to its customers.
WAT’s global pharmaceuticals business, its largest single market and major revenue driver, has been gaining traction over the last few quarters and fuelling the growth of Waters Division. The company has a strong presence in the chromatography instrument and pharmaceuticals markets and expects to reap handsome profits from these markets. Additionally, research-intensive product launches coupled with its strong REIMS technology are showing strong future prospects.
However, WAT’s debt level remains a burden, given its recent acquisitions. Also, financial markets in certain foreign countries, especially in Eastern Europe, have been experiencing economic inconsistencies. Such challenging macro conditions, coupled with currency fluctuations, have restricted sales growth rate in recent times. WAT expects these concerns to persist and dampen some of its sales growth momentum to some extent.
Nevertheless, in the last four trailing quarters, WAT has reported a positive average earnings surprise of 2.3%, beating estimates all through.
WATERS CORP Price and EPS Surprise
WATERS CORP Price and EPS Surprise | WATERS CORP Quote
Currently, WAT has a Zacks Rank #2 (Buy) but that could change following its second-quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: WAT beats on earnings. Adjusted earnings per share came in at $1.58, significantly higher than the Zacks Consensus Estimate of $1.45.
Revenue: Revenues of $537 million came above the Zacks Consensus Estimate of $522 million.
Key Stats: Waters witnessed robust sales growth in Asia (particularly China) and Europe. Also, strong market traction in the bio/pharmaceutical end markets drove the impressive results.
Stock Price: WAT shares were inactive following the release. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on this WAT earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>